Scientists track survival in rare HTLV-1 Virus-Linked cancers
NCT ID NCT05237245
First seen Nov 20, 2025 · Last updated Jun 21, 2026 · Updated 36 times
Summary
This study follows 69 adults infected with HTLV-1, a virus that can cause a rare type of blood cancer (adult T-cell leukemia/lymphoma). Researchers are tracking how long people survive, whether they receive treatment or not, and analyzing their blood and tumor cells. The goal is to better understand the disease and what affects outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HTLV-1 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could provide a clearer picture of how HTLV-1 infection progresses and what factors influence survival, potentially guiding future treatments.
What could go wrong
This is an observational study with only 69 participants, so results may not apply to everyone. It does not test any new treatment, so no direct benefit to participants is expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.